Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

Study ID
NCT02903914

Study type
Interventional

Study phase
Phase 1/Phase 2

Study status
Completed

Trial Acronym

Trial Summary

This study is an open-label Phase 1/Phase 2 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors.

More informations

Trial Starting Date

Sep 14,2016

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit

260